Oropharyngeal and Hypopharyngeal squamous cell carcinoma
Conditions
Interventions
Sub-mucosal administrations of alpha-GalactosylCeramide pulsed DCs are performed on day 7 and 10 after the entry.
Sub-mucosal administrations of non pulsed DCs are performed on day 7 and 10 after the
Sponsors
Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with stage IV oropharyngeal and hypopharyngeal squamous cell carcinoma, who have achieved Complete Response after the standard treatment; Patients within 8 weeks after receiving the determination of Complete Response; Performance status 0-2; Normal bone marrow, liver and renal functions.
Exclusion criteria
Exclusion criteria: Patients who have: uncontrolled diabetes mellitus, pulmonary fibrosis, and/or infection; a history of hepatitis; a positive response for hepatitis B surface antigen, or human immunodeficiency virus (HIV), hepatitis C virus, or human T-lymphotrophic virus antibodies; serious cardiac disease; recieived concurrent corticosteroid therapy; pregnancy or lactation; autoimmune diseases; been judged to be inappropriate to participate in this study by principle investigator or co-investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relapse-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Two-year relapse rate Overall survival rate Specific immune responses of peripheral blood Frequency and seriousness of adverse events | — |
Countries
Japan
Contacts
Public ContactDaiju Sakurai
Graduate School of Medicine, Chiba University epartment of Otorhinolaryngology, Head and Neck Surgery
Outcome results
None listed